<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0604245159
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Jaypirca
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIRTOBRUTINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        20872.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ELI LILLY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ELI LILLY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Eli Lilly and Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>JAYPIRCA is a prescription medicine used to treat adults with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment and who have already received at least 2 treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic lymphocytic leukaemia (CLL): a type of cancer affecting white blood cells called lymphocytes. This medicine is used when the cancer has come back (relapsed), or treatment has not worked (refractory).</p><p>&nbsp;</p><p>It is not known if JAYPIRCA is safe and effective in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take </strong><strong>JAYPIRCA</strong><strong>:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_94b613f9-1045-4a2e-ae6d-bcb7965389ff \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to pirtobrutinib or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4e5c76b0-63f0-497b-b76a-815d60a96377 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Talk to your doctor or pharmacist or nurse before taking JAYPIRCA.</p><p><strong>&nbsp;</strong></p><p><strong>Before taking JAYPIRCA, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an infection or have been advised that you are at increased risk of infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had recent surgery or plan to have surgery. Your healthcare provider may stop JAYPIRCA for any planned medical, surgical, or dental procedure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have bleeding problems or are taking a blood thinner medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or had heart rhythm problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of other cancers including skin cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. JAYPIRCA can harm your unborn baby.</p><p><strong>Females who are able to become pregnant:</strong></p><p>o&nbsp;&nbsp; Your healthcare provider will do a pregnancy test before starting treatment with JAYPIRCA.</p><p>o&nbsp;&nbsp; You should use effective birth control (contraception) during treatment with JAYPIRCA and for 1 week after your last dose of JAYPIRCA.</p><p>o&nbsp;&nbsp; Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with JAYPIRCA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if JAYPIRCA passes into your breast milk. Do not breastfeed during treatment with JAYPIRCA and for 1 week after your last dose of JAYPIRCA.</p><p><strong>Tell your healthcare provider about all the medicines you take,</strong> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking JAYPIRCA with certain other medicines may affect how JAYPIRCA or the other medicines work and can cause side effects.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_42262af2-7ab4-4bff-9460-48ca11fec029 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>No studies have been conducted to determine the effects of pirtobrutinib on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take JAYPIRCA exactly as your healthcare provider tells you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not change your dose or stop taking JAYPIRCA unless your healthcare provider tells you to do so.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take JAYPIRCA tablets 1 time each day at about the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take JAYPIRCA with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow JAYPIRCA tablets whole with water. Do not cut, crush, or chew the tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose of JAYPIRCA, take it as soon as you remember on the same day. If it has been more than 12 hours from the time you usually take JAYPIRCA, skip the missed dose, and take your next dose on the next day at your usual time.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more </strong><strong>JAYPIRCA</strong><strong> than you should</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f6cde575-dde2-4e5d-912a-70edcbdb7f1c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt;mso-no-proof:yes'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you take too much JAYPIRCA, call your healthcare provider or go to the nearest hospital emergency room right away.</p><p>&nbsp;</p><p><strong>If you stop taking </strong><strong>JAYPIRCA</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>JAYPIRCA can cause serious side effects, including: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections</strong> can happen during treatment with JAYPIRCA. These infections can be serious and may lead to death. Your healthcare provider may prescribe vaccines and certain medicines if you have an increased risk of getting infections. Tell your healthcare provider right away if you develop fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with JAYPIRCA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bleeding problems (hemorrhage) </strong>can happen during treatment with JAYPIRCA and can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you develop any signs or symptoms of bleeding, including:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp; blood in your stools or black stools (looks like tar)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp; pink or brown urine</p><p>o&nbsp;&nbsp;&nbsp;&nbsp; unexpected bleeding, or bleeding that is severe or you cannot control</p><p>o&nbsp;&nbsp;&nbsp;&nbsp; vomit blood or vomit blood that looks like coffee grinds</p><p>o&nbsp;&nbsp;&nbsp;&nbsp; cough up blood or blood clots &nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased bruising</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in your speech</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache that lasts a long time&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr></tbody></table><p><strong>Decrease in blood cell counts. </strong>Decrease in blood cell counts (white blood cells, platelets, and red blood cells) are common with JAYPIRCA, but can also be severe. This may increase your risk of infection, bleeding, and anemia. Your healthcare provider should do blood tests to check your blood counts regularly during treatment with JAYPIRCA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart rhythm problems </strong>Heart rhythm problems including atrial fibrillation and atrial flutter<strong> </strong>have happened in people treated with JAYPIRCA<strong>. </strong>Your risk for heart rhythm problems may be increased if you have high blood pressure or have had heart rhythm problems in the past. Tell your healthcare provider if you develop any of the following signs or symptoms:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; fast or irregular heartbeat (palpitations)</p><p>o&nbsp;&nbsp; dizziness</p><p>o&nbsp;&nbsp; fainting</p></td><td style="vertical-align:top"><p>o&nbsp;&nbsp; chest discomfort</p><p>o&nbsp;&nbsp; shortness of breath</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Second primary cancers. </strong>New cancers have happened in people during treatment with JAYPIRCA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with JAYPIRCA. Use sun protection when you are outside in sunlight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver Problems.</strong> Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with JAYPIRCA. Your healthcare provider will do blood tests to check your liver before and during treatment with JAYPIRCA. Tell your healthcare provider or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.</p><p>Your healthcare provider may decrease your dose, temporarily stop, or permanently stop treatment with JAYPIRCA if you develop severe side effects.</p><p><strong>The most common side effects of JAYPIRCA in MCL include:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle, joint, and bone pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;The most common side effects of JAYPIRCA in CLL/SLL include:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen hands, ankles or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection</p></td></tr></tbody></table><p>These are not all the possible side effects of JAYPIRCA.</p><p>Call your doctor for medical advice about side effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store JAYPIRCA below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; JAYPIRCA comes in a bottle with a child-resistant cap.</p><p>&nbsp;</p><p><strong>Keep JAYPIRCA and all medicines out of the sight and reach of children.</strong></p><p><strong>&nbsp;</strong></p><p>Do not use this medicine after the expiry date which is stated on the label after abbreviation used for expiry date. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Active ingredient: </strong>pirtobrutinib</p><p><strong>Inactive ingredients: </strong>Microcrystalline Cellulose, Lactose Monohydrate, Croscarmellose Sodium, Silicon Dioxide, Magnesium Stearate, Color Mixture Blue 03K105008, Purified Water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What JAYPIRCA looks like and contents of the pack

JAYPIRCA tablets are supplied as follows:
-	50 mg: Blue, film coated, arc-triangle shaped tablets debossed with “Lilly 50” on one side and “6902” on the other side.
-	Bottle with child-resistant closure. Each bottle contains 30 tablets.
-	100 mg: Blue, film coated, round tablets debossed with “Lilly 100” on one side and “7026” on the other side.
-	Bottle with child-resistant closure. Each bottle contains 30 tablets.
-	Bottle with child-resistant closure. Each bottle contains 60 tablets.

Not all pack sizes may be marketed.

General information about the safe and effective use of JAYPIRCA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use JAYPIRCA for a condition for which it was not prescribed. Do not give JAYPIRCA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about JAYPIRCA that is written for health professionals.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA</p><p>And</p><p>Lilly del Caribe, Inc. 12.6 KM 65th Infantry Road (PR01) Carolina, Puerto Rico (PR) 00985 United States (USA)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was issued in June 2024
Version 2


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">جايبيركا هو دواء يُصرف بوصفة طبيّة يُستخدم لعلاج البالغين الذين يعانون من:</p><p dir="RTL">&middot;&nbsp; سرطان الغدد الليمفاوية لخلايا الوشاح (MCL) المعاود أو الذي لم يستجب للعلاج السابق والذين تلقوا سابقًا علاجين على الأقل للسرطان الذي يعانون منه، بما في ذلك دواء مثبط لتيروزين كيناز بروتون (BTK).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp; ابيضاض الدم اللمفاوي المزمن (CLL): نوع من السرطان يصيب خلايا الدم البيضاء التي تُسمّى الخلايا اللمفاويّة. يُستخدم هذا الدواء عند عودة السرطان (انتكاسة)، أو عندما لم ينجح العلاج (سرطان مقاوم للعلاج).</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان دواء جايبيركا آمنًا وفعالًا لدى الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عليك الامتناع عن أخذ جايبيركا إذا كنت:&nbsp; </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من حساسيّة تجاه مادة بيرتوبروتينيب أو أحد المكوّنات الأخرى لهذا الدواء (المذكورة في الفقرة 6).</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدّث مع الطبيب أو الصيدلي أو الممرّض قبل البدء بأخذ جايبيركا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل أخذ جايبيركا، أخبر مقدّم الرعاية الصحيّة الذي يتابعك عن جميع حالاتك الصحيّة، بما في ذلك إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بحالة عدوى أو معرّضًا لخطر متزايد للإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خضعت مؤخرًا لعمليّة جراحيّة أو تنوي إجراء عمليّة جراحيّة. قد يوقف مقدّم الرعاية الصحيّة الذي يتابعك جايبيركا لأيّ إجراء مقرّر أكان طبيًّا أو جراحيًّا أو في الأسنان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل في النزيف أو تتناول دواء لسيلان الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني أو عانيت في السابق من مشاكل في النظم القلبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك ارتفاع في ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أُصبت في الماضي بأنواع سرطان أخرى بما فيها سرطان الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من مشاكل في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من مشاكل في الكبد</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كنتِ حاملاً أو تنوين الحمل إذ يمكن أن يؤذي جايبيركا الجنين.</p><p dir="RTL"><strong>الإناث القادرات على الحمل:</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم مقدّم الرعاية الصحيّة الذي يتابعك بإجراء اختبار حمل قبل بدء العلاج بجايبيركا .</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليكِ استخدام وسيلة فعّالة لمنع الحمل أثناء العلاج بجايبيركا ولمدّة أسبوع بعد الجرعة الأخيرة من جايبيركا.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعلمي على الفور مقدّم الرعاية الصحيّة الذي يتابعك إذا أصبحت حاملاً أو تعتقدين أنك حامل أثناء العلاج بجايبيركا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ تُرضعين طفلك أو تنوين الإرضاع. من غير المعروف ما إذا كان جايبيركا يمرّ في حليب الثدي. لا تُرضعي أثناء العلاج بجايبيركا ولمدّة أسبوع بعد الجرعة الأخيرة من جايبيريكا.</p><p dir="RTL"><strong>أخبر مقدّم الرعاية الصحيّة الذي يتابعك عن جميع الأدوية التي تتناولها،</strong> بما في ذلك الأدوية التي تُصرف من دون وصفة طبيّة والفيتامينات والمكمّلات العشبية. قد يؤثر تناول جايبيركا مع بعض الأدوية الأخرى على طريقة عمل جايبيركا أو الأدوية الأخرى ويمكن أن يسبّب آثارًا جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات </strong></p><p dir="RTL">لم يتمّ إجراء أي دراسات لتحديد تأثيرات مادة بيرتوبروتينيب على القدرة على القيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ جايبيركا تمامًا وفقًا لتعليمات مقدّم الرعاية الصحيّة الذي يتابعك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تغيّر جرعتك أو تتوقف عن تناول جايبيركا ما لم يطلب مقدّم الرعاية الصحيّة القيام بذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ أقراص جايبيركا مرّة واحدة كلّ يوم في الوقت ذاته تقريبًا كلّ يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ جايبيركا مع أو بدون طعام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابلع أقراص جايبيركا كاملة مع الماء. لا تقطع الأقراص أو تسحقها أو تمضغها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا فوّت جرعة من جايبيركا، خذها حالما تتذكّرها في اليوم ذاته. إذا مرّ أكثر من 12 ساعة على الوقت الذي عادة ما تتناول فيه جايبيركا، لا تأخذ الجرعة الفائتة، وتناول الجرعة التالية في اليوم التالي في الوقت المعتاد.</p><p dir="RTL"><strong>في حال أخذ كمية من </strong><strong>جايبيركا</strong><strong> تفوق الجرعة اللازمة</strong></p><p dir="RTL">إذا أخذت جرعة كبيرة من جايبيركا، اتّصل بمقدّم الرعاية الصحية أو توجّه إلى قسم الطوارئ في أقرب مستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقّفت عن أخذ </strong><strong>جايبيركا</strong></p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل الطبيب أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يمكن أن يسبّب جايبيركا آثارًا جانبية خطيرة تتضمّن ما يلي:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يمكن أن تحدث <strong>حالات عدوى</strong> أثناء العلاج بجايبيركا. يمكن أن تكون حالات العدوى هذه خطيرة وقد تؤدي إلى الوفاة. يمكن أن يصف لك مقدّم الرعاية الصحيّة الذي يتابعك لقاحات وأدوية معيّنة إذا كنت معرّضًا لخطر متزايد للإصابة بالعدوى. أخبر مقدّم الرعاية الصحيّة على الفور إذا أصبت بالحمى أو القشعريرات أو الضعف أو بأعراض شبيهة بالإنفلونزا أو بأي علامات أخرى من علامات العدوى أثناء العلاج بجايبيركا.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يمكن أن تحدث<strong> مشاكل نزف (نزيف</strong>) أثناء العلاج بجايبيركا ويمكن أن تكون خطيرة وقد تؤدي إلى الوفاة. قد يزداد خطر إصابتك بنزيف حاد إذا كنت تتناول أيضًا دواء مضادًا لتخثّر الدم. أخبر مقدم الرعاية الصحيّة الذي يتابعك إذا ظهرت عليك أي علامات أو أعراض نزيف، بما في ذلك:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في برازك أو براز أسود (يشبه القطران)</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الكدمات</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بول وردي اللون أو بني</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف غير متوقّع، أو نزيف شديد أو لا يمكن السيطرة عليه</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيّؤ دمًا أو التقيّؤ دمًا يشبه حبيبات البن</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مصحوب بالدم أو جلطات دمويّة</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في كلامك</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صداع يدوم طويلاً</p></td></tr></tbody></table><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انخفاض في عدد خلايا الدم.</strong> يُعدّ الانخفاض في عدد خلايا الدم (خلايا الدم البيضاء والصفائح الدموية وخلايا الدم الحمراء) أمرًا شائعًا مع جايبيركا، ولكنه قد يكون شديدًا أيضًا. قد يزيد هذا من خطر الإصابة بالعدوى والنزيف وفقر الدم. يجب على مقدّم الرعاية الصحيّة الذي يتابعك إجراء فحوصات دم للتحقق من تعداد الدم بشكل منتظم أثناء العلاج بجايبيركا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل في نظم القلب</strong> حدثت مشاكل في نظم القلب بما في ذلك الرجفان الأذيني والرفرفة الأذينيّة لدى الأشخاص المعالجين بجايبيركا. قد يزداد خطر إصابتك بمشاكل النظم القلبي إذا كنت تعاني من ارتفاع ضغط الدم أو عانيت من مشاكل في النظم القلبي في الماضي. أخبر مقدّم الرعاية الصحية الذي يتابعك إذا ظهرعليك أيّ من العلامات أو الأعراض التالية:</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة أو غير منتظمة (خفقان)</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزعاج في الصدر</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>السرطانات الأساسيّة الثانويّة.</strong> حدثت سرطانات جديدة لدى أشخاص أثناء العلاج بجايبيركا، بما في ذلك سرطانات الجلد أو الأعضاء الأخرى. سيقوم مقدّم الرعاية الصحيّة الذي يتابعك بفحصك بحثًا عن سرطانات أخرى أثناء العلاج بجايبيركا. استخدم واقي الشمس عندما تكون في الخارج تحت أشعّة الشمس.</p><p dir="RTL"><strong>مشاكل الكبد</strong>. قد تحدث مشاكل في الكبد قد تكون حادة أو مهددة للحياة، أو قد تؤدي إلى الوفاة، لدى الأشخاص الذين يتلقون العلاج بجايبيركا. سيجري مقدّم الرعاية الصحيّة الذي يتابعك اختبارات دم لفحص الكبد قبل العلاج بجايبيركا وأثناءه. أخبر مقدّم الرعاية الصحية الذي يتابعك أو احصل على المساعدة الطبية على الفور إذا ظهرت عليك أي علامات تدلّ على مشاكل في الكبد، بما في ذلك ألم أو انزعاج في المعدة أو البول الداكن اللون أو اصفرار الجلد والعينين.&nbsp;</p><p dir="RTL">قد يخفّض مقدّم الرعاية الصحية الذي يتابعك جرعتك، أو يوقف العلاج بجايبيركا مؤقتًا، أو بشكل دائم إذا عانيت من آثار جانبيّة شديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تشمل الآثار الجانبيّة الأكثر شيوعًا لجايبيركا في سرطان الغدد الليمفاوية لخلايا الوشاح</strong><strong> </strong><strong>ما يلي:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفّس</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات والمفاصل والعظام</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدّم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم</p></td><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تشمل الآثار الجانبيّة الأكثر شيوعًا لجايبيركا </strong><strong>في ابيضاض الدم اللمفاوي المزمن</strong><strong>/ سرطان الغدد الليمفاوية الصغيرة ما يلي:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التعب</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الإسهال</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تورّم اليدين أو الكاحلين أو القدمين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الصداع</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الغثيان</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">ليست هذه كلّ الآثار الجانبيّة المحتملة لجايبيركا.</p><p dir="RTL">اتصل بطبيبك للحصول على مشورة طبيّة بشأن الاثار الجانبيّة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خزّن جايبيركا في درجة حرارة أقل من 30 درجة مئوية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يأتي جايبيريكا في زجاجة ذات غطاء مقاوم للأطفال.</p><p dir="RTL"><strong>إحفظ جايبيركا وكلّ الأدوية بعيدًا عن </strong>نظر الأطفال ومتناولهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي الامتناع عن استخدام هذا الدواء بعد تاريخ انتهاء صلاحيته المحدّد على الملصق، بعد المختصر المستخدم للإشارة إلى تاريخ انتهاء الصلاحية. ويُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي الامتناع عن رمي أيّ أدوية في مياه الصرف الصحي أو مع النفايات المنزلية، واستشارة الصيدلي حول كيفية التخلّص من الأدوية التي توقّفت عن استخدامها. من شأن هذه التدابير المساهمة في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة: </strong>بيرتوبروتينيب</p><p dir="RTL"><strong>المكوّنات غير الفعالة</strong>: سلولوز دقيق البلوريّة، لاكتوز أحادي الهيدرات، كروسكارميلوز الصوديوم، ثاني أكسيد السيليكون، &nbsp;ستيارات المغنيزيزم،03K105008 مزيج اللون الأزرق ، ماء مقطّر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف هو شكل جايبيركا ومحتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تأتي أفراص جايبيركا على الشكل الآتي:</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>50 ملغ: أقراص زرقاء، مغلّفة بطبقة رقيقة، على شكل قوس مثلّث، منقوش عليها&nbsp; &ldquo;Lilly 50&rdquo; &nbsp;من جهة واحدة و&ldquo;6902&rdquo; على الجهة الأخرى.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>زجاجة ذات غطاء مقاوم للأطفال. تحتوي كلّ زجاجة على 30 قرصًا.&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>100 ملغ: أقراص مستديرة، زرقاء، مغلّفة بطبقة رقيقة منقوش عليها&nbsp; &ldquo;Lilly 100&rdquo; &nbsp;من جهة واحدة و&ldquo;7026&rdquo; على الجهة الأخرى.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>زجاجة ذات غطاء مقاوم للأطفال. تحتوي كلّ زجاجة على 30 قرصًا.&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>زجاجة ذات غطاء مقاوم للأطفال. تحتوي كلّ زجاجة على 60 قرصًا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تكون جميع أحجام العلب متوافرة في بلدك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات عامة حول الاستعمال الآمن والفعّال لجايبيركا.</strong></p><p dir="RTL">توصف الأدوية أحيانًا لغايات غير تلك المذكورة في نشرة معلومات المريض. لا تستعمل جايبيركا لحالة لم يتمّ وصفه لأجلها. لا تعطِ جايبيركا لأشخاص آخرين، حتى ولو كانت لديهم أعراضك ذاتها. فقد يؤذيهم. يمكنك أن تطلب من الصيدليّ أو من مقدّم الرعاية الصحيّة الحصول على معلومات مكتوبة للمتخصصين في مجال الصحّة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p dir="RTL">شركة إيلي ليلي وشركاه. مركز الشركة ليلي إنديانابوليس، ولاية إنديانا 46285، الولايات المتّحدة الأمريكية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع </strong></p><p dir="RTL">شركة إيلي ليلي وشركاه. مركز الشركة ليلي إنديانابوليس، ولاية إنديانا 46285، الولايات المتّحدة الأمريكية.</p><p dir="RTL">و</p><p dir="RTL">&nbsp;ليلي دل كريبي، Inc، 12.6 كلم، 65 طريق إنفنتري (PR01). كارولينا، بويرتو ريكو، .00985 (PR) الولايات المتحدة الأمريكية.(USA)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أُعدّت النشرة المريض هذه في يونيو 2024 
النسخة 2 


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                JAYPIRCA 50mg tablets, for oral use
JAYPIRCA 100mg tablets, for oral use

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.1	General description
Pirtobrutinib is a kinase inhibitor. It is an orally available, small molecule ATP-competitive inhibitor of BTK. The active pharmaceutical ingredient is pirtobrutinib with the molecular formula C22H21F4N5O3 and a molecular weight of 479.44 g/mol. The chemical name for pirtobrutinib is 5-amino-3-{4-[(5-fluoro-2-methoxybenzamido)methyl]phenyl}-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-pyrazole-4-carboxamide.
 

 

Pirtobrutinib is a white to practically white to yellow to brown solid. The aqueous solubility of pirtobrutinib is considered practically insoluble, or insoluble, across the pH 1 to pH 7 range.
Pirtobrutinib tablets are supplied as 50 mg or 100 mg film-coated, debossed tablets for oral administration. 

2.2	Qualitative and quantitative composition

Each tablet contains inactive ingredients of croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose and silicon dioxide. The tablet film coating material contains FD&C Blue #2, hypromellose, titanium dioxide and triacetin. 

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets, for oral use.
Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with “Lilly 50” on one side and “6902” on the other side. 
Each 100 mg tablet is blue, round, film-coated, and debossed with “Lilly 100” on one side and “7026” on the other side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mantle Cell Lymphoma&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3ffb8b06-181d-425c-8d6b-4ada07a88e38 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-end'></span></span></span><![endif]--></p><p>JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.</p><p>&nbsp;</p><p>This indication is approved under accelerated approval based on response rate <em>[see Pharmacodynamic properties (5.1)]. </em>Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p><p>&nbsp;</p><p><strong>Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma</strong></p><p>Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory</p><p>chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) who have been previously treated with a BTK inhibitor.<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_23793924-4676-482f-8c55-73c963b18831 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Recommended Dosage<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1094d23d-e6d1-4e02-ba09-17d223254f5e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-end'></span></span></span><![endif]--></p><p>The recommended dosage of JAYPIRCA is 200 mg orally once daily until disease progression or unacceptable toxicity.</p><p>Advise patients of the following:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Swallow tablets whole with water. Do not split, crush, or chew tablets.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Take JAYPIRCA at the same time each day. JAYPIRCA may be taken with or without food.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; If a dose of JAYPIRCA is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.&nbsp;</p><p>Dosage Modifications for Adverse Reactions<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_87f81bf5-decf-413e-8091-f5216a23bae3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Recommended dosage modifications of JAYPIRCA for adverse reactions are presented in Table 1 <em>[s</em><strong><em>ee </em></strong><em>Special warnings and precautions for use (4.4)].</em></p><p>Table 1: Recommended Dosage Modification of JAYPIRCA for Adverse Reactions<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ad8a4288-0b36-4673-8d2d-4b70da2dd2c0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Adverse Reaction</p></td><td style="vertical-align:top"><p>Occurrences Requiring Dosage Modification</p></td><td style="vertical-align:top"><p>Modification</p><p>(Starting Dosage: 200 mg once daily)</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or greater non-hematologic toxicity <sup>a</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute neutrophil count &lt; 1 to 0.5 x 10<sup>9</sup>/L with fever and/or infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Absolute neutrophil count &lt; 0.5 x 10<sup>9</sup>/L lasting 7 or more days</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Platelet count &lt; 50 to 25 x 10<sup>9</sup>/L with bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Platelet count &lt; 25 x 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p><strong>First occurrence</strong></p></td><td style="vertical-align:top"><p>Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at original dosage (200 mg once daily)<sup>a</sup>.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Second occurrence</strong></p></td><td style="vertical-align:top"><p>Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 100 mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Third occurrence</strong></p></td><td style="vertical-align:top"><p>Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 50 mg once daily.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fourth occurrence</strong></p></td><td style="vertical-align:top"><p>Discontinue JAYPIRCA.</p></td></tr></tbody></table><p>Dose modification is not recommended for asymptomatic lymphocytosis. Asymptomatic lipase increase may not necessarily warrant dose modification.</p><p><sup>a</sup> Evaluate the benefit-risk before resuming treatment at the same dose for a Grade 4 non-hematological toxicity.</p><p>Dosage Modifications for Patients with Severe Renal Impairment<!--[if supportFields]><span
style='mso-bookmark:s23'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:s23'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>
DOCVARIABLE vault_nd_c0a4d7d2-ceb4-4b64-a5df-8951dcf1f73f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:s23'></span><span style='mso-element:field-end'></span><![endif]--></p><p>For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA <em>[see Undesirable effects (4.8), Pharmacokinetic properties </em><em>(5.2)</em><em>]. </em>No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_33be195c-d4d0-4aae-b485-60819c744fe8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_58293ddd-6d45-468b-8d78-357098d737eb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Avoid concomitant use of strong CYP3A inhibitors with JAYPIRCA <em>[see Interaction with other medicinal products and other forms of interaction </em><em>(4.5)</em>,<em> Pharmacokinetic properties </em><em>(5.2)</em><em>]</em>. If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the JAYPIRCA dose by 50&nbsp;mg. If the current dosage is 50 mg once daily, interrupt JAYPIRCA treatment for the duration of strong CYP3A inhibitor use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the JAYPIRCA dose that was taken prior to initiating the strong CYP3A inhibitor.</p><p>Dosage Modifications for Concomitant Use with CYP3A Inducers<!--[if supportFields]><span
style='mso-bookmark:s25'><span style='mso-bookmark:s24'></span></span><span
style='mso-element:field-begin'></span><span style='mso-bookmark:s25'><span
style='mso-bookmark:s24'><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>
DOCVARIABLE vault_nd_d36d2a38-b092-4a52-b4f4-621c8f9a80dc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:s25'><span style='mso-bookmark:s24'></span></span><span
style='mso-element:field-end'></span><![endif]--></p><p>Avoid concomitant use of strong or moderate CYP3A inducers with JAYPIRCA <em>[see Interaction with other medicinal products and other forms of interaction </em><em>(4.5)</em><em>, Pharmacokinetic properties (5.2)]</em>. If concomitant use with moderate CYP3A inducers is unavoidable and the current dosage of JAYPIRCA is 200 mg once daily, increase the dose to 300 mg. If the current dosage is 50 mg or 100 mg once daily, increase the dose by 50 mg.</p><p><strong>&nbsp;</strong></p><p><u>Method of administration</u><!--[if supportFields]><u><span style='mso-bidi-font-size:
11.0pt;mso-ansi-language:EN-US'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_dffe18ef-6b16-4678-96d0-279640d5bfd0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u><![endif]--><u>&nbsp;</u><!--[if supportFields]><u><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-element:field-end'></span></span></u><![endif]--></p><p>Oral use<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_37db43d3-9c1f-4d0b-a928-3613dc65329b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None known.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Infections<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_922c4fd3-2430-436a-859c-c3bf96f3e5c8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-end'></span></span></span><![endif]--></p><p>Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients treated with JAYPIRCA. Across clinical trials, Grade 3 or higher infections occurred in 24-26% of 704 patients, most commonly pneumonia (14-22%%), with fatal infections occurring in 4. 4-8% of patients. Sepsis occurred in 4.3-6% of patients and febrile neutropenia in 2.6-4.1%. In patients with CLL/SLL, Grade 3 or higher infections occurred in 29-33% of patients, with fatal infections occurring in 3.4-8%. Opportunistic infections after treatment with JAYPIRCA have included, but are not limited to, <em>Pneumocystis jirovecii</em> pneumonia and fungal infection <em>[see Undesirable effects (4.8)]</em><em>.</em><!--[if supportFields]><i><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3b534ad8-ef74-44f0-8067-990103b20591 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><p>Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients who are at increased risk for infections, including opportunistic infections. Monitor patients for signs and symptoms of infection, evaluate promptly, and treat appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <em>[see Posology and method of administration (4.2)].</em></p><p>Hemorrhage<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_184cf4f7-9633-4c5d-9273-743812c99af7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-end'></span></span></span><![endif]--></p><p>Fatal and serious hemorrhage has occurred with JAYPIRCA. Major hemorrhage (defined as Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 1.7-2.7%% of 704 patients treated with JAYPIRCA across clinical trials, including gastrointestinal hemorrhage; fatal hemorrhage occurred in 0-0. 3% of patients.&nbsp;Bleeding of any grade, excluding bruising and petechiae, occurred in 11-17% of patients <em>[see Undesirable effects (4.8)]</em><em>.</em><!--[if supportFields]><i><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fa2e63e9-e5d9-4d02-91f5-2ac157852536 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><p>&nbsp;</p><p>Major hemorrhage occurred in 0.9-2.2% 2.3% of patients taking JAYPIRCA without antithrombotic agents and 0.5-0.9% % of patients taking JAYPIRCA with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co‑administered with JAYPIRCA. Monitor patients for signs of bleeding. Based on severity of bleeding, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <em>[see Posology and method of administration (4.2)].</em></p><p>Consider the benefit-risk of withholding JAYPIRCA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.</p><p>Cytopenias<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_4dd96499-7866-4c99-a25e-4836cbbb80e0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>JAYPIRCA can cause cytopenias, including neutropenia, thrombocytopenia, and anemia.</p><p>Across clinical trials, Grade 3 or 4 cytopenias, including decreased neutrophils (26%), decreased platelets (12-17%%), and decreased hemoglobin (10-12%) developed in patients treated with JAYPIRCA. Grade 4 decreased neutrophilsdeveloped in 12-15%% of patients and Grade 4 decreased platelets developed in 6-9% of patients <em>[see</em><em> Undesirable effects</em><em> (4.8)].</em></p><p>Monitor complete blood counts regularly during treatment. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <em>[see Posology and method of administration (4.2)].</em></p><p>Cardiac Arrhythmias<!--[if supportFields]><span style='mso-element:field-begin'></span><span
style='font-family:"Times New Roman",serif'> DOCVARIABLE
vault_nd_527b349d-a993-453d-89a4-1063addb53ce \* MERGEFORMAT </span><span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-element:field-end'></span><![endif]--></p><p>Cardiac arrhythmias, including atrial fibrillation and atrial flutter, were reported in recipients of JAYPIRCA. Atrial fibrillation or flutter were reported in 2.6-3.6% of patients, with Grade 3 or 4 atrial fibrillation or flutter reported in 1.5-1.7% of 704 patients across clinical trials <em>[see Adverse Reactions </em><em>(6.1)</em><em>]</em>. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred in 0.5-1.7% of patients. Patients with cardiac risk factors, such as hypertension, or previous arrhythmias may be at increased risk.</p><p>Monitor for signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea) and manage appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <em>[see Posology and method of administration (4.2)].</em></p><p>Second Primary Malignancies<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_874802a6-b55b-45aa-a336-2ac23842c543 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Second primary malignancies, including non-skin carcinomas, developed in 7-9% of 704 patients treated with JAYPIRCA monotherapy across clinical trials. The most frequent malignancy was non-melanoma skin cancer, reported in 3.4-4.6% of 704 patients. Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor patients for the development of second primary malignancies.</p><p>&nbsp;</p><p><strong>Hepatotoxicity, Including Drug-Induced Liver Injury </strong></p><p>Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including JAYPIRCA. Evaluate bilirubin and transaminases at baseline and throughout treatment with JAYPIRCA. For patients who develop abnormal liver tests after JAYPIRCA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold JAYPIRCA. Upon confirmation of DILI, discontinue JAYPIRCA.</p><p>Embryo-Fetal Toxicity<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2046045a-69dc-4610-840e-e31c2ec6f5e2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Based on findings in animals, JAYPIRCA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of pirtobrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended dose of 200 mg once daily. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose <em>[see Fertility, pregnancy and lactation (4.6)].</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of Other Drugs on JAYPIRCA<!--[if supportFields]><span
style='mso-bookmark:_Hlk116899390'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk116899390'><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'> DOCVARIABLE
vault_nd_6f82dd70-b47b-45f3-8ccd-e749a5104cdb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bookmark:_Hlk116899390'></span><span style='mso-element:field-end'></span><![endif]--></p><p><u>Strong CYP3A Inhibitors</u></p><p>Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure <em>[see</em> <em>Pharmacokinetic properties </em><em>(5.2)</em><em>]</em>, which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant use of strong CYP3A inhibitors is unavoidable, reduce the JAYPIRCA dosage <em>[see Posology and method of administration (4.2)].</em><!--[if supportFields]><i><span lang=EN-GB
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f4f573b6-e889-41d9-9e86-5b6d1a0e0235 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span></i><![endif]--></p><p>Strong or Moderate CYP3A Inducers</p><p>Concomitant use of JAYPIRCA with a strong or moderate CYP3A inducer decreased pirtobrutinib systemic exposure <em>[see Pharmacokinetic properties</em><em> </em><em>(5.2)</em><em>]</em>, which may reduce JAYPIRCA efficacy. Avoid concomitant use of JAYPIRCA with strong or moderate CYP3A inducers. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dosage <em>[see Posology and method of </em>administration (4.2)].</p><p>If the current pirtobrutinib dose is 200 mg, consider increasing the dose to 300 mg once daily when coadministering with moderate or strong CYP3A inducers.Effect of JAYPIRCA on Other Drugs<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8215f46d-1683-48bb-b813-e9685ec325c7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-end'></span></span></span><![endif]--></p><p><u>Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates</u></p><p>JAYPIRCA is a P-gp inhibitor, a moderate CYP2C8 and BCRP inhibitor, and a weak CYP2C19 and CYP3A inhibitor. Concomitant use of JAYPIRCA with sensitive P-gp, CYP2C8, BCRP, CYP2C19, or CYP3A substrates increased their plasma concentrations <em>[see Pharmacokinetic properties</em><em> </em><em>(5.2)</em><em>],</em> which may increase the risk of adverse reactions related to these substrates for drugs which are sensitive to minimal concentration changes. Follow recommendations for sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP substrates provided in their approved product labeling.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f4b92f09-47d0-43bc-9602-1887f5a3643a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Risk Summary</p><p>Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman. There are no available data on JAYPIRCA use in pregnant women to evaluate for a drug-associated risk. In an animal reproduction study, administration of pirtobrutinib to pregnant rats during organogenesis resulted in adverse developmental outcomes, including structural abnormalities, altered fetal growth, and embryo-fetal mortality, at maternal exposures approximately 3-times those in patients at the recommended daily dose of 200 mg (see <em>Data</em>). Advise pregnant women of the potential risk to a fetus.</p><p>&nbsp;</p><p>The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</p><p>Data</p><p>Animal Data</p><p>In an embryo-fetal development study in rats, pregnant animals were administered oral doses of pirtobrutinib at up to 500&nbsp;mg/kg twice daily during the period of organogenesis. Doses &ge; 375 mg/kg twice daily caused decreased fetal body weights and increased incidence of malformations and variations in the urinary tract (including absent or abnormal ureters and kidneys), reproductive tract (malpositioned ovaries and misshapen uterus), and bone (misshapen sternebrae). At 500&nbsp;mg/kg twice daily, total resorption was observed. At 375 mg/kg twice daily in rats, the maternal systemic exposures (AUC) were approximately 3 times the human exposure at 200 mg once daily.</p><p>Lactation<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c8293c26-31f7-48f3-a014-aea13282e4a6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Risk Summary</p><p>There are no data on the presence of pirtobrutinib in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with JAYPIRCA and for one week after the last dose.</p><p>Females and Males of Reproductive Potential<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c0ec660a-aa00-41ff-a41d-bd2af7d9b6b4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman <em>[see Fertility, pregnancy and lactation (4.6)].</em></p><p>Pregnancy Testing</p><p>Verify pregnancy status in females of reproductive potential prior to initiating JAYPIRCA.</p><p>Contraception</p><p>Females</p><p>Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been conducted to determine the effects of pirtobrutinib on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp; Infections <em>[s</em><strong><em>ee </em></strong><em>Special warnings and precautions for use (4.4)].</em></p><p>&middot;&nbsp;&nbsp;&nbsp; Hemorrhage <em>[s</em><strong><em>ee </em></strong><em>Special warnings and precautions for use (4.4)].</em></p><p>&middot;&nbsp;&nbsp;&nbsp; Cytopenias <em>[s</em><strong><em>ee </em></strong><em>Special warnings and precautions for use (4.4)].</em></p><p>&middot;&nbsp;&nbsp;&nbsp; Atrial Fibrillation and Atrial Flutter <em>[s</em><strong><em>ee </em></strong><em>Special warnings and precautions for use (4.4)].</em></p><p>&middot;&nbsp;&nbsp;&nbsp; Second Primary Malignancies <em>[s</em><strong><em>ee </em></strong><em>Special warnings and precautions for use (4.4)].</em></p><p>&middot;&nbsp;&nbsp;&nbsp; Hepatotoxicity, including DILI<em> [see Special warnings and precautions for use (4.4)]</em></p><p>Clinical Trials Experience<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_74e75cbb-0439-434a-95eb-82f2a8303e1c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-end'></span></span></span><![endif]--></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population.</p><p>The data in the WARNINGS AND PRECAUTIONS reflect exposure to JAYPIRCA as a single-agent, administered at 200&nbsp;mg once daily in 704 patients with hematologic malignancies in the BRUIN and the BRUIN-CLL-321 studies. Among these 704 patients, the median duration of exposure was 10 months in BRUIN and 15 months in BRUIN CLL-321, 62% were exposed for at least 6 months and 45% were exposed for at least one year in BRUIN, while 78% were exposed for at least 6 months and 66% were exposed for at least one year in BRUIN CLL-321.</p><p>The most common (&ge; 30%) adverse reactions, including laboratory abnormalities, across clinical trials were: decreased neutrophil count, decreased hemoglobin, fatigue, decreased platelets, decreased leukocytes, and decreased lymphocyte count.</p><p><u>&nbsp;</u></p><p><u>Mantle Cell Lymphoma</u></p><p><em>&nbsp;</em></p><p>BRUIN&ndash; Open-label, international, multicohort, single-arm study in previously treated patients with B-cell malignancies Cohort: Patients with MCL who received a prior BTK inhibitor</p><p><em>&nbsp;</em></p><p>The safety of JAYPIRCA was evaluated in the BRUIN trial in patients with MCL who received a prior BTK inhibitor <em>[s</em><strong><em>ee </em></strong><em>Special warnings and precautions for use (4.4)]. </em>The trial required a platelet count &ge; 50 x 10<sup>9</sup>/L, absolute neutrophil count &ge; 0.75 x 10<sup>9</sup>/L, hepatic transaminases &le; 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding or grade &ge; 3 arrhythmia with a prior BTK inhibitor, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.</p><p>Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (n = 128); 36% were exposed for 6 months or longer and 10% were exposed for at least one year. The median number of prior therapies was 3 (range: 1-9). The median age was 71 years (range: 46 to 88 years) and 80% of patients were male. Race was reported for all patients; 78% were White, 14% were Asian, 2.3% were Black, and 2.3% were Hispanic or Latino.</p><p>Serious adverse reactions occurred in 38% of patients who received JAYPIRCA. Serious adverse reactions that occurred in &ge; 2% of patients were pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 7% of patients, most commonly due to infections (4.7%) including COVID-19 (3.1% of all patients).</p><p>Adverse reactions led to dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions that resulted in dosage modification in &gt; 5% of patients included pneumonia and neutropenia. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in &gt; 1% of patients included pneumonia.</p><p>The most common adverse reactions (&ge; 15%), excluding laboratory terms, were fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.</p><p>Table 2 summarizes select adverse reactions in BRUIN.</p><p>Table 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse Reactions (&ge; 10%) in Patients with MCL Who Received JAYPIRCA<!--[if supportFields]><span style='font-size:11.0pt;
font-family:"Times New Roman",serif;color:windowtext'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_5b1b097a-0d75-42ef-834b-0641cbb9aab3
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:692px"><thead><tr><td rowspan="2" style="vertical-align:top">&nbsp;</td><td colspan="2" style="vertical-align:top"><p>JAYPIRCA</p><p>200 mg once daily</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p>N = 128</p></td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p><strong>Adverse Reactions</strong><sup> a</sup></p></td><td style="vertical-align:bottom"><p>All Grades (%)</p></td><td style="vertical-align:bottom"><p>Grade 3-4 (%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>General Disorders</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Edema</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Musculoskeletal and Connective Tissue Disorders</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>3.9</p></td></tr><tr><td style="vertical-align:top"><p>Arthritis or arthralgia</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Gastrointestinal Disorders</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Respiratory, thoracic, and mediastinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Injury</p></td></tr><tr><td style="vertical-align:top"><p>Bruising</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Infections</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>16<sup> b</sup></p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infections</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathy</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage</p></td><td style="vertical-align:top"><p>11<sup> c</sup></p></td><td style="vertical-align:top"><p>3.1</p></td></tr></tbody></table><p><sup>a </sup>Each term listed includes other related terms.</p><p><sup>b </sup>includes 1 fatality from COVID-19 pneumonia.</p><p><sup>c </sup>includes 1 fatality from hemorrhage.</p><p>&nbsp;</p><p>Clinically relevant adverse reactions in &lt; 10% include vision changes, memory changes, headache, urinary tract infection, herpesvirus infection, and tumor lysis syndrome.</p><p>&nbsp;</p><p>Table 3 summarizes laboratory abnormalities in BRUIN.</p><p>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Select Laboratory Abnormalities (&ge; 10%) That Worsened from Baseline in Patients with MCL Who Received JAYPIRCA<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c08df50a-aa33-4a42-b4d2-9975b52e362b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Laboratory Abnormality</p></td><td colspan="2" style="vertical-align:top"><p>JAYPIRCA<sup>a</sup></p><p>200 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>All Grades (%)</p></td><td style="vertical-align:top"><p>Grade 3 or 4 (%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hematology </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin decreased</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count decreased</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophil count decreased</p></td><td style="vertical-align:top"><p>36</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocyte count decreased</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p><strong>Chemistry</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine increased</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Calcium decreased</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>AST increased</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Potassium decreased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Sodium decreased</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>4.4</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>ALT increased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1.6</p></td></tr><tr><td style="vertical-align:top"><p>Potassium increased</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.8</p></td></tr></tbody></table><p><sup>a </sup>&nbsp;The denominator used to calculate the rate varied from 90 to 127 based on the number of patients with a baseline value and at least one post-treatment value.</p><p>&nbsp;</p><p>Grade 4 laboratory abnormalities in &gt; 5% of patients included neutrophils decreased (10%), platelets decreased (7%), and lymphocytes decreased (6%).</p><p><u>Lymphocytosis</u>: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased &ge; 50% from baseline and a post-baseline value &ge; 5,000/&micro;L) occurred in 34% of MCL patients in BRUIN. The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 2.1 weeks, and the median duration was 11 weeks.</p><p><u>&nbsp;</u></p><p><u>Chronic Lymphocytic Leukaemia/</u>Small Lymphocytic Lymphoma<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b0850551-8278-48c3-a662-15726c990c9e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><u>&nbsp;</u></p><p>The data described below reflect exposure to JAYPIRCA (200 mg once daily) in 223 CLL/SLL patients from one single-arm, open-label clinical trial (BRUIN) and 116 CLL/SLL patients from one randomized controlled clinical trial (BRUIN CLL-321).<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_56e528f0-476f-40f0-ab21-f6500e8c0572 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Table 4: Adverse Drug Reactions in Patients with CLL/SLL Treated with Pirtobrutinib as a Single Agent in BRUIN</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:577px"><tbody><tr><td><p><strong>System Organ Class (MedDRA)</strong></p></td><td><p><strong>Event</strong></p></td><td><p><strong>All Grades </strong></p><p><strong>(%)</strong></p><p><strong>N=223</strong></p></td><td><p><strong>Grade &ge;</strong><strong>3<sup>a</sup> (%)</strong></p><p><strong>N=223</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Neutropenia<sup>b</sup></p></td><td style="vertical-align:top"><p>36.3</p></td><td style="vertical-align:top"><p>30.9</p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>b</sup></p></td><td style="vertical-align:top"><p>17.9</p></td><td style="vertical-align:top"><p>10.8</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>b</sup></p></td><td style="vertical-align:top"><p>16.6</p></td><td style="vertical-align:top"><p>9.9</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocytosis<sup>b</sup></p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>5.4</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>30.0</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>18.8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>17.9</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site disorders</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>31.8</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>Edema peripheral</p></td><td style="vertical-align:top"><p>14.3</p></td><td style="vertical-align:top"><p>0.4</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>13.0</p></td><td style="vertical-align:top"><p>8.9</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning, and procedural complications</p></td><td style="vertical-align:top"><p>Contusion</p></td><td style="vertical-align:top"><p>24.2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>18.8</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>16.1</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Hematuria</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic, and mediastinal disorders</p></td><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>6.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash<sup>b</sup></p></td><td style="vertical-align:top"><p>22.4</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Petechiae</p></td><td style="vertical-align:top"><p>7.2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hematoma</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>0.3</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp; </sup>Severity grade assignment based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.</p><p><sup>b&nbsp;&nbsp;&nbsp; </sup>Consolidated term.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 5: </strong><strong>Adverse Drug Reactions in Patients with CLL/SLL Treated with Pirtobrutinib as a Single Agent in BRUIN CLL-321 </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:577px"><tbody><tr><td><p><strong>System Organ Class (MedDRA)</strong></p></td><td><p><strong>Event</strong></p></td><td><p><strong>All Grades </strong></p><p><strong>(%)</strong></p><p><strong>N=116</strong></p></td><td><p><strong>Grade &ge;</strong><strong>3<sup>a</sup> (%)</strong></p><p><strong>N=116</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Neutropenia<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;26.7</p></td><td style="vertical-align:top"><p>20.7</p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>b</sup></p></td><td style="vertical-align:top"><p>20.7</p></td><td style="vertical-align:top"><p>11.2</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>b</sup></p></td><td style="vertical-align:top"><p>9.5</p></td><td style="vertical-align:top"><p>7.8</p></td></tr><tr><td style="vertical-align:top"><p>Lymphocytosis<sup>b</sup></p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>4.3</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>16.4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site disorders</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>1.7</p></td></tr><tr><td style="vertical-align:top"><p>Edema peripheral</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>22.4</p></td><td style="vertical-align:top"><p>17.2</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>10.3</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning, and procedural complications</p></td><td style="vertical-align:top"><p>Contusion</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>1.7</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Hematuria</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic, and mediastinal disorders</p></td><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash<sup>b</sup></p></td><td style="vertical-align:top"><p>16.4</p></td><td style="vertical-align:top"><p>2.6</p></td></tr><tr><td style="vertical-align:top"><p>Petechiae</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hematoma</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp; </sup>Severity grade assignment based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.</p><p><sup>b&nbsp;&nbsp;&nbsp; </sup>Consolidated term.</p><p><u>&nbsp;</u></p><p>Pediatric Use<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8047a8d3-f75f-4f17-a3e8-0c16fac3fff9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Safety and effectiveness of JAYPIRCA have not been established in pediatric patients.</p><p>Geriatric Use<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9ac137cd-0a8d-4683-b59b-c2d123a9d796 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Of the patients with MCL who received the 200 mg dose of JAYPIRCA in BRUIN, 93 (78%) were 65 years of age and older and 39 (33%) were 75 years and older<em> [s</em><strong><em>ee </em></strong><em>Special warnings and precautions for use (4.4)]. </em>Clinical studies of JAYPIRCA did not include sufficient numbers of patients with MCL who were less than<strong> </strong>65 years of age to determine whether older patients respond differently from younger adult patients. Of the patients with CLL/SLL who received the 200 mg once daily dose of JAYPIRCA in BRUIN, 68 (63%) were 65 years of age and older and 21 (19%) were 75 years and older; of the patients with CLL/SLL who received JAYPIRCA in BRUIN CLL-321, 59% were 65 years of age and older and 24% were 75 years and older <em>[see Pharmacodynamic properties</em>(5.1)<em>]</em>. No overall differences in effectiveness were observed between younger and older patients.</p><p>&nbsp;</p><p>In the pooled safety population in patients with hematologic malignancies in BRUIN and BRUIN CLL-321, 467 (66%) were 65 years of age and older, while 181 (26%) were 75 years of age and older. Patients aged 65 years and older experienced higher rates of Grade 3 and higher adverse reactions and serious adverse reactions compared to patients who were less than 65 years of age.</p><p>Renal Impairment<!--[if supportFields]><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_30cd7abc-faf2-4e4e-bdac-3996c71039b6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Severe renal impairment (eGFR15-29 mL/min) increases pirtobrutinib exposure <em>[see</em> <em>Pharmacokinetic properties</em><em> </em><em>(5.2)</em><em>]</em>. Reduce the JAYPIRCA dosage in patients with severe renal impairment <em>[see Posology and method of administration (4.2)]. </em>No dosage adjustment of JAYPIRCA is recommended in patients with mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment<em>.</em></p><p>Hepatic Impairment<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_04237dc5-1b18-4878-ae3a-0582a0c5fbe6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>No dosage adjustment of JAYPIRCA is recommended in patients with mild hepatic impairment (total bilirubin &le; upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 &times; ULN and any AST), moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 &times; ULN and any AST), or severe hepatic impairment (total bilirubin &gt; 3 &times; ULN and any AST) <em>[see Pharmacokinetic properties</em><em> </em><em>(5.2)</em><em>].</em></p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed here.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Please report adverse drug events to: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In case of overdose, use supportive therapy. There is no known antidote for pirtobrutinib overdose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3d769418-36b1-4afe-85a1-b29cfd1c8cde \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Pharmacotherapeutic group: {Antineoplastic agents, protein kinase inhibitors}, ATC code: L01EL05<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_157ff8a8-8b83-4aa9-87d6-a4f419771052 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-no-proof:yes'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Mechanism of action<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_23784837-6dc2-4d91-aedb-67f1862fcc1c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.</p><p>Pharmacodynamics<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d26268b5-1698-4e03-a85c-d18c9e401e28 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>At the recommended dosage of 200 mg once daily, pirtobrutinib trough concentrations exceeded the BTK IC<sub>96</sub>. BTK occupancy is maintained throughout the dosing interval, regardless of the intrinsic rate of BTK turnover.</p><p>Cardiac Electrophysiology</p><p>The effect of a single 900 mg dose of pirtobrutinib (equivalent to approximately 2 times higher than the concentrations achieved at steady state at the recommended dosage of 200 mg once daily) on the QTc interval was evaluated in a placebo-controlled and positive-controlled study in 30 healthy subjects. Pirtobrutinib had no clinically meaningful effect on the change in QTcF interval (i.e., &gt; 10 ms) and there was no relationship between pirtobrutinib exposure and change in QTc interval.</p><p>&nbsp;</p><p>CLINICAL STUDIES<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_9d26346c-cc82-4076-99a0-eeefc829c76a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Mantle Cell Lymphoma<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_944dbdae-aba5-499c-9f15-1f7b2edec57e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
class=PLRCharacterPlaceholderText><span style='font-size:11.0pt;font-family:
"Times New Roman",serif'><span style='mso-element:field-end'></span></span></span><![endif]--></p><p>The efficacy of JAYPIRCA in patients with MCL was evaluated in BRUIN [NCT03740529], an open-label, international, , single-arm study of JAYPIRCA as monotherapy. Efficacy was based on 120 patients with MCL treated with JAYPIRCA who were previously treated with a BTK inhibitor. JAYPIRCA was given orally at a dose of 200 mg once daily and was continued until disease progression or unacceptable toxicity. Patients with active central nervous system lymphoma or allogeneic hematopoietic stem cell transplantation (HSCT) or CAR-T cell therapy within 60 days were excluded.&nbsp;</p><p>The median age was 71 years (range: 46 to 88 years); 79% were male; 78% were White, 14% Asian, 1.7% Black or African American. Seventy-eight percent of patients had the classic/leukemic variant of MCL, 12% had pleomorphic MCL, and 11% had blastoid MCL. The simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) score was low in 15%, intermediate in 59%, and high in 26% of patients. Patients received a median number of 3 prior lines of therapy (range: 1 to 9) with 93% having received 2 or more prior lines. All received 1 or more prior lines of therapy containing a BTK inhibitor; other prior therapies included chemoimmunotherapy in 88%, HSCT in 20%, lenalidomide in 18%, and CAR‑T therapy in 9%. The most common prior BTK inhibitors received were ibrutinib (67%), acalabrutinib (30%), and zanubrutinib (8%). Patients may have received more than one prior BTK inhibitor; 83% of patients discontinued the last BTK inhibitor for refractory or progressive disease, 10% discontinued for toxicity, and 5% discontinued for other reasons.</p><p>Efficacy was based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2014 Lugano criteria. Efficacy results are shown in Table 6. Additionally, the Kaplan-Meier estimate for the DOR rate at 6 months was 65.3% (95% CI: 49.8, 77.1).</p><p>Table 6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results per IRC in Patients with MCL Previously Treated with a BTK Inhibitor <!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_4771de44-74f6-4ef0-af78-c3ccbfe58add \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'><span
style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p>Outcome</p></td><td style="vertical-align:bottom"><p>JAYPIRCA 200 mg once daily</p><p>(N = 120)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Response Rate <sup>a,b </sup></strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>ORR, n</p></td><td style="vertical-align:top"><p>60 (50%)</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI, %)</p></td><td style="vertical-align:top"><p>41, 59</p></td></tr><tr><td style="vertical-align:top"><p>CR, n</p></td><td style="vertical-align:top"><p>15 (13%)</p></td></tr><tr><td style="vertical-align:top"><p>PR, n</p></td><td style="vertical-align:top"><p>45 (38%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to Response</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Median (range), months</p></td><td style="vertical-align:top"><p>1.8 (0.8, 4.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response <sup>c</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number censored, n</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>Median DOR, months (95% CI)</p></td><td style="vertical-align:top"><p>8.3 (5.7, NE)</p></td></tr></tbody></table><p>CI, confidence interval; CR, complete response; DOR, duration of response; PR, partial response; NE, not estimable.</p><p><sup>a </sup>PET-CT scans were utilized in response assessments (in 41% of patients), with the remainder being assessed by CT scans only.</p><p><sup>b</sup> ORR using CT scan-based assessments in all patients was 48% (95% CI: 38, 57) and CR rate was 13%.</p><p><sup>c </sup>Based on Kaplan-Meier estimation. Estimated median follow-up was 7.3 months.</p><p><strong>&nbsp;</strong></p><p><strong>Chronic Lymphocytic Leukaemia</strong>/Small Lymphocytic Lymphoma</p><p><strong>&nbsp;</strong></p><p>The efficacy of Jaypirca in patients with BTK-inhibitor pretreated CLL/SLL was evaluated in a randomised, multicentre, international, open-label, actively-controlled trial (BRUIN CLL-321, Study 20020). The trial enrolled 238 patients with CLL/SLL who were previously treated with a BTK inhibitor. Patients were randomised in a 1:1 ratio to receive either Jaypirca given orally once daily at a dose of 200 mg until disease progression or unacceptable toxicity, or Investigator&rsquo;s choice:</p><p>&middot;&nbsp;&nbsp;&nbsp; Idelalisib plus a rituximab product (IR): Idelalisib 150 mg orally twice daily until disease progression or unacceptable toxicity, in combination with 8 infusions of a rituximab product (375 mg/m2 intravenously on Day 1 of Cycle 1, followed by 500 mg/m2 every 2 weeks for 4 doses and then every 4 weeks for 3 doses), with a 28-day cycle length.</p><p>&middot;&nbsp;&nbsp;&nbsp; Bendamustine plus a rituximab product (BR): Bendamustine 70 mg/m2 intravenously (Day 1 and 2 of each 28-day cycle), in combination with a rituximab product (375 mg/m2 intravenously on Day 1 of Cycle 1, then 500 mg/m2 on Day 1 of subsequent cycles), for up to 6 cycles.</p><p>&nbsp;</p><p>Randomisation was stratified by 17p deletion status (yes/no) and receipt of prior venetoclax treatment (yes/no). Of the 238 patients total, 119 were assigned to Jaypirca monotherapy, 82 to IR and 37 to BR. After confirmed disease progression, patients randomised to IR or BR had the option to cross over to Jaypirca monotherapy. Baseline characteristics were similar between treatment arms. Overall, the median age was 67 years (range: 42 to 90 years), 70&nbsp;% were male and 81&nbsp;% were White. Baseline ECOG performance status was 0 or 1 in 93% of patients and 44% of patients had Rai stage III or IV disease. Among those patients with central testing available, 57&nbsp;% (101 of 176 patients) had 17p deletion and/or TP53 mutation, 86&nbsp;% (164 of 190 patients) had unmutated IGHV, and 65&nbsp;% (97 of 149) had complex karyotype.</p><p>&nbsp;</p><p>Patients received a median number of 3 prior lines of therapy (range: 1 to 13) with 57&nbsp;% having at least 3 prior therapies and 51&nbsp;% having had prior BCL2-inhibitor therapy. The most common prior BTK inhibitors received were ibrutinib (87&nbsp;%), acalabrutinib (16&nbsp;%), and zanubrutinib (7&nbsp;%). 70&nbsp;% of patients discontinued the most recent BTK inhibitor for refractory or progressive disease, 15&nbsp;% discontinued for toxicity, and 15&nbsp;% discontinued for other reasons.</p><p>&nbsp;</p><p>Efficacy was based on progression-free survival (PFS) of pirtobrutinib monotherapy versus investigator&rsquo;s choice arm as assessed by an Independent Review Committee (IRC). The study met its primary endpoint at the prespecified time of final analysis for IRC-assessed PFS (29 Aug 2023 cut-off). At an updated analysis (29 Aug 2024 cut-off) with a median follow-up of 19.4&nbsp;months (range 0.03 to 33.3&nbsp;months) for pirtobrutinib and 17.7&nbsp;months (range 0.03 to 27.9&nbsp;months) for the investigator&rsquo;s choice arm, improved IRC-assessed PFS was observed with pirtobrutinib compared to the investigator&rsquo;s choice arm, consistent with the primary analysis. Clinically meaningful efficacy results in favour of pirtobrutinib were observed across important subgroups, including patients who discontinued prior BTK inhibitor therapy due to intolerance or progression and irrespective of number and type of prior therapies. Efficacy results are presented in Table&nbsp;7. The Kaplan-Meier curve for PFS is shown in Figure&nbsp;1.</p><p>&nbsp;</p><p><strong>Table 7: Efficacy Results per IRC in Patients with CLL/SLL Previously Treated with a BTK Inhibitor &ndash; ITT Population (Study 20020)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pirtobrutinib 200 mg once daily</p><p>(N = 119)</p></td><td style="vertical-align:top"><p>Investigator&rsquo;s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab</p><p>(N = 119)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression-free Survival<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of Events, n</p></td><td style="vertical-align:top"><p>74 (62&nbsp;%)</p></td><td style="vertical-align:top"><p>79 (66&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>Disease Progression</p></td><td style="vertical-align:top"><p>60 (50&nbsp;%)</p></td><td style="vertical-align:top"><p>66 (55&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>Death</p></td><td style="vertical-align:top"><p>14 (12&nbsp;%)</p></td><td style="vertical-align:top"><p>13 (11&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS (95&nbsp;% CI), months <sup>b</sup></p></td><td style="vertical-align:top"><p>14.0 (11.2, 16.6)</p></td><td style="vertical-align:top"><p>8.7 (8.1, 10.4)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95&nbsp;% CI) <sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.54 (0.39, 0.75)</p></td></tr><tr><td style="vertical-align:top"><p>P-value <sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0002</p></td></tr></tbody></table><p>CI, confidence interval; HR, hazard ratio.</p><p>Data cut-off date 29 Aug 2024</p><p>a&nbsp;Efficacy was assessed using the 2018 International Workshop for Chronic Lymphocytic Leukemia (CLL) guidelines</p><p>b&nbsp;Based on Kaplan-Meier estimation.</p><p>c&nbsp;Based on stratified Cox proportional hazards model.</p><p>d&nbsp;2-sided nominal p-value based on stratified log-rank test.</p><p>&nbsp;</p><p><strong>Figure 1: Kaplan-Meier Curve of IRC-Assessed PFS in Patients with CLL/SLL Previously Treated with a BTK Inhibitor in Study&nbsp;20020</strong></p><p>&nbsp;</p><p><img alt="" width="1310" height="739" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p>With a median overall survival (OS) follow-up time of 20.4&nbsp;months for pirtobrutinib and 19.2&nbsp;months in investigator&rsquo;s choice arm, 38&nbsp;patients (32.0&nbsp;%) in the pirtobrutinib arm and 32&nbsp;patients (27.0&nbsp;%) in the investigator&rsquo;s choice arm died. Median OS was 29.7&nbsp;months (95&nbsp;% CI: 27.1, NE) in the pirtobrutinib arm and not reached in the investigator&rsquo;s choice arm. The HR was 1.090&nbsp;(95% CI: 0.679, 1.749; p&nbsp;=&nbsp;0.7202). OS analysis may be confounded by the 50 out of 119&nbsp;patients who crossed over from the investigator&rsquo;s choice arm to pirtobrutinib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetics<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e2381d04-663a-4410-9f40-af19f4ba9375 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>The pharmacokinetics of pirtobrutinib were characterized in healthy subjects and in patients with cancer. Pirtobrutinib exposure (AUC) and C<sub>max</sub> increases proportionally following single oral doses ranging from 300 mg to 800 mg (1.5 to 4&nbsp;times the approved recommended dosage) and once daily doses ranging from 25 &ndash; 300 mg (0.125 to 1.5 times the recommended dosage). Steady state was achieved within 5 days of once daily dosing, and the mean (CV%) accumulation ratio was 1.63 (26.7%) based on AUC after administration of 200 mg dosages.</p><p>Following administration of the recommended dosage, the geometric mean (CV%) steady-state AUC and C<sub>max</sub> of pirtobrutinib were 92705 h*ng/mL (39%)&nbsp;and 6503 ng/ml (25%), respectively. The geometric mean (CV%) AUC<sub>0-24 </sub>and C<sub>max</sub> of pirtobrutinib on Cycle 1 Day 8 were 81800 h*ng/mL (66.6%) and 3670 ng/mL (89.5%), respectively.</p><p>Absorption</p><p>The absolute bioavailability of pirtobrutinib after a single oral 200 mg dose is 85.5% (range 75.9% to 90.9%). The median time (range) to reach peak plasma concentration (tmax) is approximately 2 hours (0.833 to 4.15 hours).</p><p>Effect of Food</p><p>No clinically significant differences in the pharmacokinetics of pirtobrutinib were observed following administration of a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) to healthy subjects. A high-fat meal decreased the C<sub>max</sub> of pirtobrutinib by 23% and delayed t<sub>max</sub> by 1 hour. There was no effect on pirtobrutinib AUC.</p><p>Distribution</p><p>The mean apparent central volume of distribution of pirtobrutinib is 34.2 L. &nbsp;Human protein binding of pirtobrutinib is 96% and is independent of concentration in vitro. Mean blood-to-plasma ratio is 0.79.</p><p>Elimination</p><p>The effective half-life of pirtobrutinib is approximately 20 hours and the mean (CV%) apparent clearance is 2.05 L/h (35.7 %).</p><p>Metabolism</p><p>Pirtobrutinib is primarily metabolized by CYP3A4 and direct glucuronidation by UGT1A8 and UGT1A9, in vitro.</p><p>Excretion</p><p>Following a single radiolabeled dose of pirtobrutinib 200 mg to healthy subjects, 37% of the dose was recovered in feces (18% unchanged) and 57% in urine (10% unchanged).</p><p>Specific Populations</p><p>There were no clinically significant differences in the pharmacokinetics of pirtobrutinib based on age (range 22 &ndash; 95 years), sex, race/ethnicity (White 83%, Asian 9%), body weight (range 35.7 &ndash; 152 kg), mild (total bilirubin &le; upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 &times; ULN and any AST), moderate (total bilirubin &gt; 1.5 to 3 &times; ULN and any AST), or severe (total bilirubin &gt; 3 &times; ULN and any AST) hepatic impairment. The effect of other races/ethnicities on the pharmacokinetics of pirtobrutinib is unknown.</p><p>&nbsp;</p><p>Patients with Renal Impairment</p><p>Following a single 200 mg oral dose, the AUC of pirtobrutinib in subjects with severe renal impairment (eGFR 15-29 mL/min) increased by 62% and mean unbound AUC increased by 68% compared to healthy subjects with normal renal function. There were no clinically significant differences in the pharmacokinetics of pirtobrutinib in subjects with mild (eGFR 60-89 mL/min) or moderate renal impairment (eGFR 30-59 mL/min). The effect of renal impairment requiring dialysis on the pharmacokinetics of pirtobrutinib is unknown.</p><p>&nbsp;</p><p>Drug Interaction Studies</p><p>Clinical Studies and Model-Informed Approaches</p><p><em>Strong CYP3A Inhibitors:</em> Co-administration of a single 200 mg dose of pirtobrutinib with itraconazole (strong CYP3A inhibitor) increased AUC<sub> </sub>of pirtobrutinib by 49%.</p><p>Moderate CYP3A Inhibitors: Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the AUC of pirtobrutinib by 30% and 20%, respectively.</p><p>Strong CYP3A inducers: Coadministration of a single 200 mg dose of pirtobrutinib with rifampin (strong CYP3A inducer) decreased the AUC of pirtobrutinib by 71%.</p><p>Moderate CYP3A Inducers: Efavirenz and bosentan (moderate CYP3A inducers) are predicted to decrease the AUC of pirtobrutinib by 49% and 27%, respectively.</p><p><em>Gastric Reducing Agents: </em>No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co‑administered with omeprazole (a proton pump inhibitor).</p><p>P-glycoprotein (P-gp) inhibitors: No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with itraconazole (P-gp inhibitor).</p><p>CYP3A Substrates: Pirtobrutinib increased the AUC and C<sub>max</sub> of orally administered midazolam (sensitive CYP3A substrate) by 70% and 58%, respectively. Pirtobrutinib did not have a clinically meaningful effect on the exposure of intravenously administered midazolam.</p><p>CYP2C8 Substrates: Pirtobrutinib increased the AUC and C<sub>max</sub> of repaglinide (sensitive CYP2C8 substrate) by 130% and 98%, respectively.</p><p>CYP2C19 Substrates: Pirtobrutinib increased the AUC and C<sub>max</sub> of omeprazole (sensitive CYP2C19 substrate) by 56% and 49%, respectively.</p><p>P-gp Substrates: A single 200 mg dose of pirtobrutinib increased the AUC and C<sub>max</sub> of digoxin (sensitive P-gp substrate) by 17% and 51%, respectively. Multiple doses of pirtobrutinib (200 mg daily) further increased the AUC and C<sub>max</sub> of digoxin (sensitive P-gp substrate) up to 35% and 55%, respectively.</p><p>BCRP Substrates: Multiple doses of pirtobrutinib (200 mg daily) increased the AUC and C<sub>max</sub> of rosuvastatin (sensitive BCRP substrate) by 140% and 146%, respectively.</p><p>CYP1A2 and CYP2C9 Substrates: Pirtobrutinib did not have a clinically meaningful effect on the exposures of caffeine (sensitive CYP1A2 substrate) or S-warfarin (moderate sensitive CYP2C9 substrate).</p><p>In Vitro Studies</p><p>Cytochrome P450 (CYP) Enzymes: Pirtobrutinib inhibits CYP2C8, CYP2C9, CYP3A, CYP1A2, CYP2B6, CYP2C19, and CYP2D6. Pirtobrutinib induces CYP3A4, CYP3A5, CYP2B6, and CYP2C19.</p><p>Transporter Systems: Pirtobrutinib inhibits P-gp and BCRP, but not OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K.&nbsp; Pirtobrutinib is not a substrate of the hepatic transporters. Pirtobrutinib is a substrate of P-gp and BCRP, but not OCT1, OATP1B1, OATP1B3, or BSEP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, mutagenesis, impairment of fertility<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8655441e-5148-4cf4-a2d8-d85946aca4fb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Carcinogenicity studies have not been conducted with pirtobrutinib.</p><p>&nbsp;</p><p>Pirtobrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay. Pirtobrutinib was aneugenic in<em> in vitro</em> micronucleus assays using human peripheral blood lymphocytes. Pirtobrutinib was not genotoxic in an <em>in vivo</em> rat bone marrow micronucleus assay at doses up to 2000 mg/kg.</p><p>&nbsp;</p><p>Studies to assess the effects of pirtobrutinib on fertility have not been conducted. In repeat-dose toxicity studies of up to 3‑months duration conducted with pirtobrutinib in rats and dogs, no effects on male or female reproductive organs were identified.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>50 mg and 100 mg Tablet Excipients:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypromellose Acetate Succinate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Microcrystalline Cellulose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose Monohydrate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Croscarmellose Sodium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Silicon Dioxide</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Magnesium Stearate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Color Mixture Blue 03K105008</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable. No material or container closure incompatibilities were identified.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>How Supplied</u></p><p>&nbsp;</p><p>JAYPIRCA tablets are supplied as follows:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p>Tablet Strength</p></td><td style="vertical-align:bottom"><p>Description</p></td><td style="vertical-align:bottom"><p>Package Configuration</p></td></tr><tr><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>Blue, film coated, arctriangle shaped tablets debossed with &ldquo;Lilly 50&rdquo; on one side and &ldquo;6902&rdquo; on the other side.</p></td><td style="vertical-align:top"><p>Bottle with child-resistant closure.</p><p>Each bottle contains 30 tablets.</p></td></tr><tr><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>Blue, film coated, round tablets debossed with &ldquo;Lilly 100&rdquo; on one side and &ldquo;7026&rdquo; on the other side.</p></td><td style="vertical-align:top"><p>Bottle with child-resistant closure.</p><p>Each bottle contains 60 tablets.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><strong>PATIENT COUNSELING INFORMATION </strong></p><p>Advise the patient to read the approved patient labeling (Patient Information).</p><p><u>Infections</u></p><p>Advise patients that JAYPIRCA can cause serious infections that may be fatal. Advise patients to report any signs or symptoms of infection (e.g., fever, chills, weakness) <em>[s<strong>ee </strong>Special warnings and precautions for use (4.4)].</em></p><p><u>Hemorrhage</u></p><p>Inform patients to report signs or symptoms of bleeding. Inform patients that JAYPIRCA may need to be interrupted for major surgeries <em>[s<strong>ee </strong>Special warnings and precautions for use (4.4)].</em></p><p><u>Cytopenias</u></p><p>Advise patients of the need for periodic monitoring of blood counts during treatment with JAYPIRCA <em>[s<strong>ee </strong>Special warnings and precautions for use (4.4)].</em></p><p>Cardiac Arrhythmias</p><p>Counsel patients to report any signs of palpitations, dizziness, fainting, chest discomfort, and shortness of breath <em>[s<strong>ee </strong>Special warnings and precautions for use (4.4)].</em></p><p><u>Second Primary Malignancies</u></p><p>Inform patients that other malignancies have been reported in patients who have been treated with JAYPIRCA, including skin cancer and other solid tumors. Advise patients to use sun protection and to have monitoring for development of other cancers <em>[s<strong>ee </strong>Special warnings and precautions for use (4.4)].</em></p><p><u>Hepatotoxicity, Including Drug-Induced Liver Injury</u></p><p>Inform patients that liver problems, including severe, life-threatening, or fatal hepatitis, drug-induced liver injury and abnormalities in liver tests, may develop during JAYPIRCA treatment. Advise patients to contact their healthcare provider immediately if they experience abdominal discomfort, dark urine, or jaundice <em>[s<strong>ee </strong>Special warnings and precautions for use (4.4)].</em></p><p><u>Embryo-Fetal Toxicity</u></p><p>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <em>[s<strong>ee </strong>Special warnings and precautions for use (4.4)</em>,<em> Fertility, pregnancy and lactation (4.6)].</em></p><p>&nbsp;</p><p>Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose <em>[see Fertility, pregnancy and lactation (4.6)].</em></p><p><u>Lactation</u></p><p>Advise women not to breastfeed during treatment with JAYPIRCA and for one week after the last dose <em>[see Fertility, pregnancy and lactation (4.6)].</em></p><p><u>Administration</u></p><p>Inform patients to take JAYPIRCA orally once daily at approximately the same time each day with or without food and how to make up a missed dose. Advise patients to swallow tablets whole with water. Advise patients not to split, crush, or chew tablets <em>[see Posology and method of administration (4.2)].</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2024
Version 2

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>